iodine valentis nahalahus
valentis uab - jood - nahalahus - 50mg 1ml 10ml 1tk
omblastys
y-mabs therapeutics a/s - iodine (131i) omburtamab - neuroblastoom - terapeutilised radiofarmatseutilised ühendid - treatment of neuroblastoma.
minims povidone iodine silmatilgad, lahus
laboratoire chauvin s.a. - joodpovidoon - silmatilgad, lahus - 5% 0.4ml 20tk
fosinopril hct actavis tablett
teva b.v. - fosinopriil+hüdroklorotiasiid - tablett - 20mg+12,5mg 50tk; 20mg+12,5mg 100tk; 20mg+12,5mg 14tk; 20mg+12,5mg 60tk
kenostart spray and dip nisakastutus-/nisasprei lahus
cid lines - jood - nisakastutus-/nisasprei lahus - 3mg 1g 25000ml 1tk; 3mg 1g 20000ml 1tk; 3mg 1g 60000ml 1tk; 3mg 1g 200000ml 1tk; 3mg 1g 1000ml 1tk; 3mg 1g 10000ml 1tk
kenostart nisakastutuslahus
cid lines - jood - nisakastutuslahus - 3mg 1g 20000ml 1tk; 3mg 1g 5000ml 1tk; 3mg 1g 10000ml 1tk; 3mg 1g 60000ml 1tk
(131i) iodomethyl norcholesterol süstelahus
cis bio international - jood(131i)norkolesterool - süstelahus - 1tk
solutio iodi spirituosa nahalahus
riga pharmaceutical plant - jood - nahalahus - 5% 20ml 1tk
thyrogen
sanofi b.v. - türeotropiin alfa - kilpnäärme kasvajad - anterior hüpofüüsi lobe hormoonid ja nende analoogid, hüpofüüsi ja hüpotaalamuse hormoonid ja nende analoogid - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.